In agreement with the above studies revealing a detrimental role of TRAIL depletion for T1DM development, additional experimental studies using either recombinant TRAIL treatment [18] or systemic adenoviral vector-mediated TRAIL gene therapy [21,22] could further substantiate the protective role of TRAIL signaling for the prevention and treatment of T1DM. Here, TNFSF10 is linked to type 1 diabetes mellitus.